ASN 002

Drug Profile

ASN 002

Alternative Names: ASN002

Latest Information Update: 20 Jul 2017

Price : $50

At a glance

  • Originator Asana BioSciences
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Janus kinase inhibitors; Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia; Myelofibrosis; Non-Hodgkin's lymphoma
  • Phase I/II Solid tumours
  • Phase I Atopic dermatitis
  • Preclinical Rheumatoid arthritis

Most Recent Events

  • 02 Jun 2017 Interim adverse events, pharmacokinetics, pharmacodynamics and efficacy data from a phase I/II trial in Solid tumours and Lymphoma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 30 May 2017 Phase-II clinical trials in Chronic lymphocytic leukaemia (Second-line therapy or greater) in USA (PO)
  • 30 May 2017 Phase-II clinical trials in Myelofibrosis (Second-line therapy or greater) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top